Shop

Author at Microdose

Microdose NewsDesk

Microdose's editorial department brings you the latest news and industry insights.

Culture

19 Oct 2024

Real-Life Fungi in Fiction: The Origins of ‘Bliss’ in The Penguin

Derived from the real-life Bleeding Tooth Fungus (Hydnellum peckii), Bliss is portrayed as a euphoric stimulant, manufactured in underground labs. While the fungus’ crimson fluid looks sinister, it isn't psychoactive....

By Microdose NewsDesk

Breaking News

10 Sep 2024

Mindstate Design Labs AI-Designed Trial Gets FDA Approval

Mindstate Design Labs has announced major news, receiving both FDA and European Medicines Agency (EMA) approval to commence human trials of its compound, MSD-001. This approval is a clinical validation...

By Microdose NewsDesk
cybin deal

Breaking News

6 Sep 2024

Psyence Biomed Announces Acquisition of Psilocybin Drug Developer Clairvoyant Therapeutics

Psyence Biomed announces acquisition Clairvoyant Therapeutics and its Phase 2b trial...

By Microdose NewsDesk

Science

30 May 2024

Interview with Terran’s CEO Sam Clark on Terran’s pipeline, including “TerXT” for schizophrenia, a new competitor to Karuna’s KarXT

We sat down with Sam Clark, CEO of Terran Biosciences, to discuss the exciting developments in their pipeline, particularly their latest schizophrenia therapeutic, TerXT. This new treatment is designed to...

By Microdose NewsDesk

Join Our Newsletter for Exclusive Updates, Stories, and More

Breaking News

26 Feb 2024

MindBio Therapeutics Announces Positive Depression Data from World-First Phase 2A Take-Home Microdosing Trial

MindBio Therapeutics has announced groundbreaking results from a Phase 2a clinical trial involving the take-home microdosing of MB22001 for treating depression. This world-first trial showcased a significant decrease in depression...

By Microdose NewsDesk

Industry

20 Dec 2023

Terran Biosciences Receives FDA Clearance for MRI Scan Technology

Terran Biosciences Receives FDA Clearance for NM-101, the industry’s first software for the analysis of neuromelanin-sensitive MRI...

By Microdose NewsDesk
news

Don’t Miss

18 Dec 2023

News You Might Have Missed: Dec 18th, 2023

Welcome to the News You Might Have Missed, a weekly roundup of psychedelic medicine news to help you catch up and stay informed...

By Microdose NewsDesk

Science

14 Dec 2023

MindMed Announces Positive Results from Phase 2b Anxiety Trial

Big news as the trial met its primary endpoint, with 50% clinical remission rate at Week 4....

By Microdose NewsDesk
maps

Breaking News

12 Dec 2023

Breaking News: MAPS Files New Drug Application With FDA for MDMA-Assisted Therapy

Historic filing marks first New Drug Application submission for any psychedelic-assisted therapy....

By Microdose NewsDesk

Follow us on social

Latest News

Reading the Brain’s Response: Enveric’s EB-003 Takes a Step Toward Human Testing

The Cost of Waiting: What Compass’s Depression Survey Means for Psychedelic Medicine

Beyond the Psychedelic Experience: Enveric Biosciences Takes Another Step Toward a New Generation of Mental Health Treatments

You Might Also Like

11 Aug 2026

Enveric Biosciences Adds Another Data Point to Its Case That EB-003 Won’t Get You High

Enveric Biosciences is trying to answer one of the trickiest questions in the psychedelic drug space: can you get the antidepressant benefits people associate with psychedelics without the trip? On...

By Madison Roberts

28 Jul 2026

FDA’s New Psychedelic Guidance Signals a Maturing Industry. Now Comes the Hard Part.

For years, the psychedelic medicine industry has operated in largely uncharted regulatory territory. Companies developing psilocybin, LSD, MDMA, and next-generation psychedelic-inspired compounds have often found themselves navigating a clinical landscape...

By Madison Roberts

13 Jul 2026

The Psychedelic Sector Has Grown Up. Wall Street Just Hasn’t Fully Realized It Yet

The sector experienced an early wave of enthusiasm fueled by bold promises, lofty valuations, and the belief that psychedelic medicine would quickly transform mental healthcare. Reality, however, proved more complicated....

By Madison Roberts

28 May 2026

Medical Psilocybin Act

New York lawmakers are officially considering the “Medical Psilocybin Act,” legislation that would create legal access to psilocybin therapy for conditions like PTSD, treatment-resistant depression, substance use disorders, end-of-life distress,...

By Madison Roberts

5 May 2026

PTSD, Policy Shifts, and the Rise of Neuroplastogens: What Enveric’s Latest Data Signals for the Field

By Madison Roberts

21 Apr 2026

Trump’s Psychedelic Fast-Track Order Changes the Timeline. It Also Redraws the Competitive Map.

President Donald Trump’s April 2026 executive order on accelerating treatments for serious mental illness does something the psychedelic industry has been waiting for, and quietly fearing. It removes ambiguity. For...

By Madison Roberts
WordPress Ads
No Result
View All Result

© 2026 JNews - Premium WordPress news & magazine theme by Jegtheme.